AstraZeneca PLC said its wholly owned subsidiary AstraZeneca Finance LLC priced a €2.55 billion Eurobond offering on Sunday, with expected closing set for September 1, 2026.
The offering comprises four tranches of fixed-rate notes, all issued under the company’s Euro Medium Term Note programme and guaranteed by AstraZeneca PLC. The largest tranche totals €750 million, maturing on September 1, 2038, with a coupon of 4.169%. A €700 million tranche maturing March 1, 2030 carries a 3.402% coupon, while €600 million due September 1, 2032 bears a 3.652% coupon. The smallest tranche, €500 million due September 1, 2035, carries a 3.923% coupon.
The London-listed biopharmaceutical company said proceeds will be used for general corporate purposes, aligning with its long-term funding strategy. The notes are admitted to the UK Financial Conduct Authority’s Official List and will trade on the London Stock Exchange’s Main Market. They have not been registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the United States without registration or an applicable exemption.
Barclays Bank PLC, Goldman Sachs International, and Morgan Stanley acted as joint book-running managers for the offering.
